PR Newswire Europe - SEROQUEL(R) Sustained Release Schizophrenia Data Presented at ECP Congress in Madrid.
Most Popular
13 Job Interview Mistakes To Avoid
3 Questions No Job Seeker Ever Wants To Be Asked?
10 Jobs That Pay $30 An Hour
Public Speaking: 7 Secrets Of Great Public Speakers
5 Regular Mistakes In Public Speaking
> LONDON, March 18 /PRNewswire/ — AstraZeneca today announced SEROQUEL(R) sustained release formulation (quetiapine fumarate sustained release) clinical trial data presented at the European Congress of Psychiatry (ECP) in Madrid. The data demonstrated that the SEROQUEL(R) sustained release formulation (quetiapine fumarate sustained release), administered once daily, significantly improved symptoms associated with schizophrenia(1) (measured by PANSS) and increased the time to psychiatric relapse(2), when administered through a 3-step dose initiation aimed at reaching the effective …
Read the rest of this article with a Free Trial at HighBeam Research.
